ioxilan
Trade name: oxilan
Small moleculeapproved
Approved
Dec 21, 1995
Ioxilan is a nonionic X-ray contrast agent approved by the United States Food and Drug Administration for X-ray imaging contrast enhancement. Ioxilan can be administered intravenously for excretory urography and contrast-enhanced computed tomography (CT) imaging of the head and body. Ioxilan can also be given intraarterially for cerebral arteriograpy, coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedDec 21, 1995
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I- Mol. weight
- 791.1119 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaIoxilan ↗
- NCATSA4YJ7J11TG ↗
- ChEMBLCHEMBL1201075 ↗
Also known as
- 5-(n-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-n-(2-hydroxyethyl)-n'-(2,3-dihydroxypropyl)isophthalamide
- ioxilan
- ioxilan
- ioxilan
- ioxilan
- ioxilan
- ioxilan
- ioxilan
- ioxilan
- ioxilan
- ioxilane
- ioxilane
- ioxilanum
- ioxilanum
- ioxitol
- n-(2,3-dihydroxypropyl)-n’-(2- hydroxyethyl)-5-[n-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide
- n-(2,3-dihydroxypropyl)-n’-(2- hydroxyethyl)-5-[n-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide
- oxilan
- oxilan
- oxilan
- oxilan
- oxilan-300
- oxilan-300
- oxilan-350
- oxilan-350